
Karen E Swales

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5540744/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discovery, 2021, 11, 92-107.	9.4	36
2	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	9.4	82
3	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2020, 26, 4777-4784.	7.0	31
4	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clinical Cancer Research, 2014, 20, 5672-5685.	7.0	66
5	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. Clinical Cancer Research, 2014, 20, 5908-5917.	7.0	38